CL43489B - Compuestos derivados de difenilazetidinona y su sal farmaceuticamente aceptable; composicion faramceutica; compuestos intermediarios; procedimiento para preparar la composicion farmaceutica; y uso de los compuestos para tratar la hiperlipidemia, sint - Google Patents

Compuestos derivados de difenilazetidinona y su sal farmaceuticamente aceptable; composicion faramceutica; compuestos intermediarios; procedimiento para preparar la composicion farmaceutica; y uso de los compuestos para tratar la hiperlipidemia, sint

Info

Publication number: CL43489B
Authority: CL; Chile
Prior art keywords: compounds; pharmaceutical composition; difenilazetidinona; sint; procedure
Prior art date: 2003-04-01

Application number

CL200400708A

Other languages

English (en)

Inventor

Gerhard Frick Wendelin Jaehne

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-01

Filing date

2004-04-01

Publication date

2005-01-21

2004-04-01 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2005-01-21 Application granted granted Critical

2005-01-21 Publication of CL43489B publication Critical patent/CL43489B/es

Links

150000001875 compounds Chemical class 0.000 title 3
239000008194 pharmaceutical composition Substances 0.000 title 2
208000031226 Hyperlipidaemia Diseases 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

CL200400708A 2003-04-01 2004-04-01 Compuestos derivados de difenilazetidinona y su sal farmaceuticamente aceptable; composicion faramceutica; compuestos intermediarios; procedimiento para preparar la composicion farmaceutica; y uso de los compuestos para tratar la hiperlipidemia, sint CL43489B (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10314610A DE10314610A1 (de)	2003-04-01	2003-04-01	Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung

Publications (1)

Publication Number	Publication Date
CL43489B true CL43489B (es)	2005-01-21

Family

ID=33103147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200400708A CL43489B (es)	2003-04-01	2004-04-01	Compuestos derivados de difenilazetidinona y su sal farmaceuticamente aceptable; composicion faramceutica; compuestos intermediarios; procedimiento para preparar la composicion farmaceutica; y uso de los compuestos para tratar la hiperlipidemia, sint

Country Status (43)

Country	Link
US (2)	US7205290B2 (es)
EP (2)	EP1613589B1 (es)
JP (1)	JP2006522040A (es)
KR (1)	KR20050119180A (es)
CN (2)	CN100361970C (es)
AR (1)	AR043783A1 (es)
AT (2)	ATE386020T1 (es)
AU (1)	AU2004226287B2 (es)
BR (1)	BRPI0408920A (es)
CA (1)	CA2520689A1 (es)
CL (1)	CL43489B (es)
CR (1)	CR7995A (es)
CY (2)	CY1107398T1 (es)
DE (3)	DE10314610A1 (es)
DK (2)	DK1862455T3 (es)
EC (1)	ECSP056071A (es)
ES (2)	ES2322876T3 (es)
GT (1)	GT200400058A (es)
HN (1)	HN2004000109A (es)
HR (1)	HRP20050870A2 (es)
JO (1)	JO2493B1 (es)
MA (1)	MA27753A1 (es)
ME (1)	MEP41408A (es)
MX (1)	MXPA05010128A (es)
MY (1)	MY136269A (es)
NI (1)	NI200500164A (es)
NO (1)	NO20055001L (es)
NZ (1)	NZ542751A (es)
PA (1)	PA8599401A1 (es)
PE (1)	PE20050011A1 (es)
PL (2)	PL1862455T3 (es)
PT (2)	PT1862455E (es)
RS (1)	RS51146B (es)
RU (1)	RU2334737C2 (es)
SA (1)	SA04250154B1 (es)
SI (2)	SI1862455T1 (es)
SV (1)	SV2004001756A (es)
TN (1)	TNSN05244A1 (es)
TW (1)	TW200504009A (es)
UA (1)	UA80754C2 (es)
UY (1)	UY28253A1 (es)
WO (1)	WO2004087655A1 (es)
ZA (1)	ZA200506708B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1609702A (en) *	2000-12-21	2002-07-01	Aventis Pharma Gmbh	Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
EP1902046B1 (en)	2005-06-20	2009-12-02	Schering Corporation	Piperidine derivatives useful as histamine h3 antagonists
US7067689B1 (en)	2005-07-08	2006-06-27	Microbia, Inc.	Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US20080319218A1 (en) *	2007-06-22	2008-12-25	Andreas Haubrich	Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
US20080319221A1 (en) *	2007-06-22	2008-12-25	Bernd Junker	Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007029612A1 (de) *	2007-06-27	2009-01-08	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Pentahydroxyhexylcarbamoylundekan- säurebenzylester
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) *	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
CN101939009B (zh) *	2008-02-05	2013-07-17	哈博生物科学公司	药学固体形式
WO2009112203A1 (de) *	2008-03-14	2009-09-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur herstellung eines diphenylazetidinons
DE102008059772A1 (de)	2008-12-01	2010-06-02	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung eines Diphenylazetidinons
DE102010015123A1 (de)	2010-04-16	2011-10-20	Sanofi-Aventis Deutschland Gmbh	Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10426480B2 (en) *	2015-04-29	2019-10-01	Covidien Lp	Cutting ring assembly with rigid cutting member

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US576470A (en) *		1897-02-02		Boiler-furnace
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5756740A (en) *	1992-04-08	1998-05-26	Eastman Kodak Company	Process for the preparation of binary sensitizing dyes
FR2713225B1 (fr)	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
US5631365A (en) *	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) *	1994-11-18	1997-05-27	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0876379A1 (en)	1996-01-17	1998-11-11	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
US5756470A (en) *	1996-10-29	1998-05-26	Schering Corporation	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja)	1997-07-16	2001-07-31	ノボノルディスクアクティーゼルスカブ	縮合化１，２，４−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
BR9908706A (pt)	1998-03-12	2000-11-21	Teijin Ltd	Derivado de benzofuril-alfa-pirona, composição farmacêutica, acentuador de metabolismo de lipìdeos, inibidor de biossìntese de triglicerìdeos, agente redutor de triglicerìdeos do sangue, agente elevador de hdl do sangue, agente profilático para a arteriosclerose, e, agente de tratamento para a arteriosclerose
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
CN1495198A (zh)	1998-12-07	2004-05-12	�о��Ӧ�ÿ�ѧЭ��ɷ��޹�˾	胰高血糖素样肽-1的类似物
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
WO2000064876A1 (en)	1999-04-28	2000-11-02	Aventis Pharma Deutschland Gmbh	Tri-aryl acid derivatives as ppar receptor ligands
EP1177187B1 (en)	1999-04-28	2007-07-25	Sanofi-Aventis Deutschland GmbH	Di-aryl acid derivatives as ppar receptor ligands
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
ATE333448T1 (de)	1999-06-18	2006-08-15	Merck & Co Inc	Arylthiazolidinedione und aryloxa zolidinedion- derivate
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
DE60004066T2 (de)	1999-07-29	2004-04-15	Eli Lilly And Co., Indianapolis	Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
DE50011035D1 (de) *	1999-09-01	2005-09-29	Aventis Pharma Gmbh	Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU2001233622A1 (en)	2000-02-25	2001-09-03	Novo-Nordisk A/S	Inhibition of beta cell degeneration
WO2001083451A1 (en)	2000-04-28	2001-11-08	Asahi Kasei Kabushiki Kaisha	Novel bicyclic compounds
CA2408486A1 (en)	2000-05-11	2001-11-15	Bristol-Myers Squibb Company	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
SE0001899D0 (sv)	2000-05-22	2000-05-22	Pharmacia & Upjohn Ab	New compounds
HUP0004741A2 (hu)	2000-11-28	2002-12-28	Sanofi-Synthelabo	Kémiai eljárás tiazolszármazékok előállítására és új intermedier
AU1609702A (en) *	2000-12-21	2002-07-01	Aventis Pharma Gmbh	Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
DE10139416A1 (de)	2001-08-17	2003-03-06	Aventis Pharma Gmbh	Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6884812B2 (en) *	2001-08-31	2005-04-26	Aventis Pharma Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
JP4436129B2 (ja) *	2001-08-31	2010-03-24	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
US7176194B2 (en) *	2002-06-19	2007-02-13	Sanofi-Aventis Deutschland Gmbh	Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) *	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds

2003
- 2003-04-01 DE DE10314610A patent/DE10314610A1/de not_active Withdrawn
2004
- 2004-02-24 JO JO200418A patent/JO2493B1/en active
- 2004-03-16 PT PT07016889T patent/PT1862455E/pt unknown
- 2004-03-16 PL PL07016889T patent/PL1862455T3/pl unknown
- 2004-03-16 AT AT04720854T patent/ATE386020T1/de not_active IP Right Cessation
- 2004-03-16 PL PL04720854T patent/PL1613589T3/pl unknown
- 2004-03-16 ME MEP-414/08A patent/MEP41408A/xx unknown
- 2004-03-16 SI SI200431100T patent/SI1862455T1/sl unknown
- 2004-03-16 HR HR20050870A patent/HRP20050870A2/xx not_active Application Discontinuation
- 2004-03-16 DE DE502004009059T patent/DE502004009059D1/de not_active Expired - Lifetime
- 2004-03-16 EP EP04720854A patent/EP1613589B1/de not_active Expired - Lifetime
- 2004-03-16 DE DE502004006195T patent/DE502004006195D1/de not_active Expired - Lifetime
- 2004-03-16 DK DK07016889T patent/DK1862455T3/da active
- 2004-03-16 UA UAA200510204A patent/UA80754C2/uk unknown
- 2004-03-16 CN CNB2004800084976A patent/CN100361970C/zh not_active Expired - Fee Related
- 2004-03-16 MX MXPA05010128A patent/MXPA05010128A/es active IP Right Grant
- 2004-03-16 PT PT04720854T patent/PT1613589E/pt unknown
- 2004-03-16 RU RU2005133631/04A patent/RU2334737C2/ru not_active IP Right Cessation
- 2004-03-16 RS YUP-2005/0719A patent/RS51146B/sr unknown
- 2004-03-16 WO PCT/EP2004/002690 patent/WO2004087655A1/de not_active Ceased
- 2004-03-16 DK DK04720854T patent/DK1613589T3/da active
- 2004-03-16 SI SI200430681T patent/SI1613589T1/sl unknown
- 2004-03-16 EP EP07016889A patent/EP1862455B1/de not_active Expired - Lifetime
- 2004-03-16 NZ NZ542751A patent/NZ542751A/en unknown
- 2004-03-16 CN CNA2007101491852A patent/CN101139306A/zh active Pending
- 2004-03-16 AU AU2004226287A patent/AU2004226287B2/en not_active Ceased
- 2004-03-16 ES ES07016889T patent/ES2322876T3/es not_active Expired - Lifetime
- 2004-03-16 KR KR1020057018705A patent/KR20050119180A/ko not_active Ceased
- 2004-03-16 BR BRPI0408920-0A patent/BRPI0408920A/pt not_active IP Right Cessation
- 2004-03-16 CA CA002520689A patent/CA2520689A1/en not_active Abandoned
- 2004-03-16 ES ES04720854T patent/ES2298731T3/es not_active Expired - Lifetime
- 2004-03-16 JP JP2006504695A patent/JP2006522040A/ja active Pending
- 2004-03-16 AT AT07016889T patent/ATE423766T1/de not_active IP Right Cessation
- 2004-03-29 HN HN2004000109A patent/HN2004000109A/es unknown
- 2004-03-29 PE PE2004000330A patent/PE20050011A1/es not_active Application Discontinuation
- 2004-03-30 TW TW093108581A patent/TW200504009A/zh unknown
- 2004-03-30 AR ARP040101052A patent/AR043783A1/es unknown
- 2004-03-30 PA PA20048599401A patent/PA8599401A1/es unknown
- 2004-03-31 GT GT200400058A patent/GT200400058A/es unknown
- 2004-03-31 US US10/813,954 patent/US7205290B2/en not_active Expired - Fee Related
- 2004-03-31 UY UY28253A patent/UY28253A1/es unknown
- 2004-03-31 MY MYPI20041165A patent/MY136269A/en unknown
- 2004-03-31 SV SV2004001756A patent/SV2004001756A/es not_active Application Discontinuation
- 2004-04-01 CL CL200400708A patent/CL43489B/es active
- 2004-06-09 SA SA04250154A patent/SA04250154B1/ar unknown
2005
- 2005-08-22 ZA ZA200506708A patent/ZA200506708B/en unknown
- 2005-09-19 CR CR7995A patent/CR7995A/es unknown
- 2005-09-22 NI NI200500164A patent/NI200500164A/es unknown
- 2005-09-30 MA MA28529A patent/MA27753A1/fr unknown
- 2005-09-30 EC EC2005006071A patent/ECSP056071A/es unknown
- 2005-09-30 TN TNP2005000244A patent/TNSN05244A1/en unknown
- 2005-10-27 NO NO20055001A patent/NO20055001L/no not_active Application Discontinuation
2007
- 2007-03-26 US US11/690,993 patent/US7772429B2/en not_active Expired - Fee Related
2008
- 2008-04-17 CY CY20081100429T patent/CY1107398T1/el unknown
2009
- 2009-05-11 CY CY20091100503T patent/CY1109055T1/el unknown

Also Published As

Publication number	Publication date
CA2520689A1 (en)	2004-10-14
RU2334737C2 (ru)	2008-09-27
ES2322876T3 (es)	2009-06-30
EP1613589A1 (de)	2006-01-11
SV2004001756A (es)	2004-11-18
GT200400058A (es)	2004-11-10
CR7995A (es)	2006-09-22
HRP20050870A2 (en)	2006-10-31
CY1109055T1 (el)	2014-07-02
NZ542751A (en)	2007-05-31
MEP41408A (en)	2011-02-10
SI1613589T1 (sl)	2008-06-30
DE502004006195D1 (de)	2008-03-27
UY28253A1 (es)	2004-11-08
ZA200506708B (en)	2007-01-31
PT1613589E (pt)	2008-03-27
ATE386020T1 (de)	2008-03-15
CN1768034A (zh)	2006-05-03
AU2004226287B2 (en)	2010-03-18
PL1862455T3 (pl)	2009-07-31
PA8599401A1 (es)	2004-10-08
CN100361970C (zh)	2008-01-16
DK1862455T3 (da)	2009-06-02
BRPI0408920A (pt)	2006-03-28
SA04250154B1 (ar)	2007-10-29
JP2006522040A (ja)	2006-09-28
NI200500164A (es)	2006-01-11
US20050020563A1 (en)	2005-01-27
ES2298731T3 (es)	2008-05-16
US7772429B2 (en)	2010-08-10
ATE423766T1 (de)	2009-03-15
TNSN05244A1 (en)	2007-06-11
JO2493B1 (en)	2009-10-05
UA80754C2 (en)	2007-10-25
TW200504009A (en)	2005-02-01
EP1862455B1 (de)	2009-02-25
WO2004087655A1 (de)	2004-10-14
MXPA05010128A (es)	2005-11-16
EP1613589B1 (de)	2008-02-13
ECSP056071A (es)	2006-01-27
US7205290B2 (en)	2007-04-17
DK1613589T3 (da)	2008-06-09
PL1613589T3 (pl)	2008-07-31
EP1862455A2 (de)	2007-12-05
KR20050119180A (ko)	2005-12-20
US20070197498A1 (en)	2007-08-23
MA27753A1 (fr)	2006-02-01
MY136269A (en)	2008-09-30
EP1862455A3 (de)	2007-12-12
RS51146B (sr)	2010-10-31
SI1862455T1 (sl)	2009-06-30
RS20050719A (sr)	2008-04-04
HK1087697A1 (zh)	2006-10-20
DE10314610A1 (de)	2004-11-04
RU2005133631A (ru)	2006-03-10
HN2004000109A (es)	2008-02-21
PE20050011A1 (es)	2005-02-28
CY1107398T1 (el)	2012-12-19
DE502004009059D1 (de)	2009-04-09
AU2004226287A1 (en)	2004-10-14
AR043783A1 (es)	2005-08-10
NO20055001L (no)	2005-10-27
PT1862455E (pt)	2009-04-23
CN101139306A (zh)	2008-03-12

Publication	Publication Date	Title
CL43489B (es)	2005-01-21	Compuestos derivados de difenilazetidinona y su sal farmaceuticamente aceptable; composicion faramceutica; compuestos intermediarios; procedimiento para preparar la composicion farmaceutica; y uso de los compuestos para tratar la hiperlipidemia, sint
CL2004001267A1 (es)	2005-04-22	Compuestos derivados de quinazolina, inhibidor de quinasa; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para preparar un medicamento para tratar trastornos proliferativos celulares tales como ateroesclerosis,
DK1656347T3 (da)	2011-01-10	Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
BRPI0410727A (pt)	2006-06-20	composto, composição farmacêutica, e, uso de um composto
EE04799B1 (et)	2007-04-16	Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
DK1158992T3 (da)	2003-12-29	Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
ZA200409862B (en)	2006-05-31	Benzofused heteroaryl derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
DK1448195T3 (da)	2007-02-12	N-adamantylmethylderivater og mellemprodukter som farmaceutiske præparater og fremgangsmåde til fremstilling deraf
CY2015003I1 (el)	2015-12-09	Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
BG66085B1 (bg)	2011-03-31	Фенилаланинови производни
BRPI0108395B8 (pt)	2021-05-25	derivados de pirrolopirimidinona, processos de preparação e uso
DE60140814D1 (de)	2010-01-28	N-phenyl-2-pyrimidine-amine derivatives
PL1730131T3 (pl)	2012-10-31	Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
UY26258A1 (es)	2000-12-29	Derivados de 8-fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-ona.
NO20013254L (no)	2001-12-31	Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem
BRPI0312649A2 (pt)	2017-05-16	compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
BRPI0519124A2 (pt)	2008-12-23	composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
PT1282616E (pt)	2004-10-29	Derivados de hidroxifenil-piperidin-4-ilideno-metil-benzamida para o tratamentoda dor
NO20042805L (no)	2004-07-02	Nye forbindelser og deres anvendelse innen medisin, fremgangsmate for deres fremstilling og farmaoytiske sammensetninger som inneholder dem
EE200200393A (et)	2003-10-15	Glüburiidi ravimkoostis
HUP0301683A3 (en)	2004-11-29	Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral indopeptidase, their intermediates, process for their preparation, pharmaceutical compositions containing them and their use
BRPI0411673A (pt)	2006-08-08	composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
ITMI20020189A0 (it)	2002-02-01	Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
UY29085A1 (es)	2006-03-31	Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BRPI0312413A2 (pt)	2016-08-02	compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos